Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Sarcoma 39Lymphoma 38Lymphoma, Large B-Cell, Diffuse 28Lymphoma, Non-Hodgkin 22Osteosarcoma 15Burkitt Lymphoma 14Hodgkin Disease 13Testicular Neoplasms 11Recurrence 9Leukemia 9Neuroectodermal Tumors, Primitive, Peripheral 8Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, Follicular 8Lymphoma, B-Cell, Marginal Zone 8Teratoma 7Ovarian Neoplasms 7Lymphoma, Mantle-Cell 7Leukemia, Lymphocytic, Chronic, B-Cell 7Testicular Germ Cell Tumor 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Neuroblastoma 6Carcinoma, Embryonal 6Breast Neoplasms 6Rhabdomyosarcoma 5Lymphoma, Large-Cell, Anaplastic 5Endodermal Sinus Tumor 5Central Nervous System Neoplasms 5Urinary Bladder Neoplasms 4Neoplasms, Germ Cell and Embryonal 4Lymphoma, B-Cell 4

Interventions

trebananib 1selurampanel 1saracatinib 1perifosine 1elacestrant 1Trabectedin 1Thalidomide 1Temozolomide 1Sunitinib 1RAD1901 1Postmortem Imaging 1Paclitaxel 1Mass Spectrometry 1Magnetic Resonance Spectroscopy 1Injections 1Imatinib Mesylate 1Ifosfamide 1High-Energy Shock Waves 1Fulvestrant 1Doxorubicin 1Chromatography, High Pressure Liquid 1Biopsy 1BI 2536 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma, Endometrial Stromal × Ifosfamide × Clear all
NCT06277154 2025-07-24

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

HRYZ Biotech Co.

Phase 2 Recruiting
148 enrolled
GynecologicSarcoma

Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Endometrial Stromal, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡